Radius Health, Inc. (NASDAQ:RDUS – Get Rating) has been given a consensus recommendation of “Hold” by the six analysts that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating and five have issued a hold rating on the company. The average twelve-month price target among brokers that have covered the stock in the last year is $8.60.
Several brokerages have recently commented on RDUS. Bank of America upgraded Radius Health from an “underperform” rating to a “neutral” rating and set a $8.00 price objective on the stock in a research report on Wednesday, June 8th. StockNews.com cut Radius Health from a “buy” rating to a “hold” rating in a report on Wednesday, May 11th. The Goldman Sachs Group decreased their target price on Radius Health from $9.00 to $8.00 and set a “neutral” rating for the company in a research report on Tuesday, May 24th. Finally, SVB Leerink increased their target price on Radius Health from $7.00 to $10.00 and gave the stock a “market perform” rating in a research report on Friday, June 24th.
Shares of RDUS stock opened at $10.48 on Friday. The company has a market cap of $498.85 million, a P/E ratio of -6.81 and a beta of 0.54. The stock has a 50 day simple moving average of $7.22 and a two-hundred day simple moving average of $7.48. Radius Health has a fifty-two week low of $4.97 and a fifty-two week high of $23.00.
I know–you’ve heard options trading is tough, but is it really tougher than the market is right now?
NO! “Options Trading Made Easy” by pro-trader Chuck Hughes gives traders the best options in an unpredictable market…
Get your copy now!
Radius Health (NASDAQ:RDUS – Get Rating) last announced its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by ($0.18). The company had revenue of $43.16 million during the quarter, compared to the consensus estimate of $51.42 million. During the same quarter last year, the firm posted ($0.34) earnings per share. On average, research analysts predict that Radius Health will post -0.18 EPS for the current year.
In related news, major shareholder Target N. V. Biotech purchased 477,824 shares of the business’s stock in a transaction on Wednesday, May 18th. The shares were bought at an average cost of $5.57 per share, with a total value of $2,661,479.68. Following the transaction, the insider now owns 8,733,538 shares of the company’s stock, valued at $48,645,806.66. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 1.73% of the stock is currently owned by company insiders.
Institutional investors have recently modified their holdings of the stock. Bellevue Group AG raised its holdings in Radius Health by 7.1% in the 1st quarter. Bellevue Group AG now owns 8,318,714 shares of the biopharmaceutical company’s stock valued at $73,454,000 after acquiring an additional 550,000 shares during the last quarter. Rubric Capital Management LP raised its holdings in Radius Health by 89.4% in the 4th quarter. Rubric Capital Management LP now owns 6,959,305 shares of the biopharmaceutical company’s stock valued at $48,158,000 after acquiring an additional 3,284,305 shares during the last quarter. Velan Capital Investment Management LP raised its holdings in Radius Health by 416.4% in the 1st quarter. Velan Capital Investment Management LP now owns 1,421,500 shares of the biopharmaceutical company’s stock valued at $12,552,000 after acquiring an additional 1,146,219 shares during the last quarter. Acadian Asset Management LLC raised its holdings in Radius Health by 341.1% in the 1st quarter. Acadian Asset Management LLC now owns 591,132 shares of the biopharmaceutical company’s stock valued at $5,217,000 after acquiring an additional 457,107 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. raised its holdings in Radius Health by 6.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 434,121 shares of the biopharmaceutical company’s stock valued at $3,834,000 after acquiring an additional 26,506 shares during the last quarter.
About Radius Health (Get Rating)
Radius Health, Inc, a biopharmaceutical company, focuses on addressing unmet medical needs in the areas of bone health, orphan diseases, and oncology. The company’s commercial product is TYMLOS, an abaloparatide injection for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide-SC, which is in Phase III clinical trials for the treatment of osteoporosis in men; abaloparatide-TD, a transdermal system that is in Phase III clinical trials to treat postmenopausal women with osteoporosis; Elacestrant (RAD1901), a selective estrogen receptor degrader, which is in Phase III clinical trials for the treatment of hormone-receptor positive breast cancer; and RAD011, which is in Phase II clinical trials for treatment of hyperphagia related to Prader-Willi syndrome.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Should you invest $1,000 in Radius Health right now?
Before you consider Radius Health, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Radius Health wasn’t on the list.
While Radius Health currently has a “Hold” rating among analysts, top-rated analysts believe these five stocks are better buys.
Source: marketbeat.com